Catalyst

Slingshot members are tracking this event:

Karyopharm's (KPTI) Selinexor in Quadruple Refractory Multiple Myeloma 3 Months Extended PDUFA date under priority review due July 6, 2019

Source Link:
https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-fda-extension-review-period-selinexor-new

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
KPTI Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jul 03, 2019
Occurred Source:
https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-fda-approval-xpoviotm-selinexor-treatment
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Selinexor, Quadruple Refractory Multiple Myeloma, Pdufa Date, Pdufa Extension
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.